Fig. 9From: A macrophage related signature for predicting prognosis and drug sensitivity in ovarian cancer based on integrative machine learningMacrophages-related signature (MRS)-based treatment strategy for ovarian cancer. The IC50 values of 5-Fluorouracil (A), Cisplatin(B), Fludarabine(C), Cyclophosphamide (D), Fulvestrant (E), Mitoxantrone (F), Topotecan(G), Venetoclax (H), Bortezomib (I), Erlotinib (J), Savolitinib (K), Selumetinib (L) in ovarian cancer patients with high and low risk scoreBack to article page